TY  - CHAP
M1  - Book, Section
TI  - Immune Cell Therapy: Dendritic Cell and Natural Killer Cell Therapy
A1  - Weinstock, Matthew
A1  - Avigan, David
A2  - Kaushansky, Kenneth
A2  - Prchal, Josef T.
A2  - Burns, Linda J.
A2  - Lichtman, Marshall A.
A2  - Levi, Marcel
A2  - Linch, David C.
Y1  - 2021
N1  - 
T2  - Williams Hematology, 10e
AB  - SUMMARYSince  their  discovery  in  the  early  1970s,  dendritic  cells  (DCs)  and  natural  killer  (NK)  cells  have  tantalized  immunologists  and  cancer  researchers  with  their  immunotherapeutic  potential  to  control  certain  neoplasms,  including  the  hematologic  malignancies.  The  current  generation  of  DC-based  vaccinations  against  acute  myelogenous  leukemia  and  myeloma  has  demonstrated  promise  in  this  regard.  Early-phase  clinical  trials  of  allogeneic  NK  cells,  both  in  haploidentical  allogeneic  hematopoietic  stem  cell  transplant  and  as  a  stand-alone  treatment,  have  also  found  encouraging  results.  Future  directions  of  research  will  include  efforts  to  augment  the  immune  response  to  DC-based  vaccination  and  allogeneic  NK  cells.  These  approaches  are  in  clinical  trials.  Further  laboratory  research  is  exploring  the  nature,  function,  and  regulation  of  DCs  and  NK  cells  in  the  tumor  microenvironment.  These  efforts  should  result  in  more  efficient  and  effective  DC-  and  NK  cell–based  immune  effector  cell  therapies  with  enhanced  clinical  activity  against  the  hematologic  malignancies.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - hemonc.mhmedical.com/content.aspx?aid=1180478006
ER  -